Taisho Pharmaceutical Co., Ltd, Kita-ku, Saitama-shi, Saitama, Japan.
Bioorg Med Chem Lett. 2010 Jul 1;20(13):3965-8. doi: 10.1016/j.bmcl.2010.04.134. Epub 2010 May 4.
Acetyl-CoA carboxylases (ACCs), the rate limiting enzymes in de novo lipid synthesis, play important roles in modulating energy metabolism. The inhibition of ACC has demonstrated promising therapeutic potential for treating obesity and type 2 diabetes mellitus in transgenic mice and preclinical animal models. We describe herein the structure-based design and synthesis of a novel series of disubstituted (4-piperidinyl)-piperazine derivatives as ACC inhibitors. Our structure-based approach led to the discovery of the indole derivatives 13i and 13j, which exhibited potent in vitro ACC inhibitory activity.
乙酰辅酶 A 羧化酶(ACCs)是从头合成脂质的限速酶,在调节能量代谢中发挥重要作用。在转基因小鼠和临床前动物模型中,ACCs 的抑制已被证明对治疗肥胖症和 2 型糖尿病具有广阔的治疗前景。本文描述了基于结构的新型二取代(4-哌啶基)哌嗪衍生物类 ACC 抑制剂的设计与合成。我们的基于结构的方法发现了吲哚衍生物 13i 和 13j,它们表现出很强的体外 ACC 抑制活性。